Skip Navigation LinksHome > April 2015 - Volume 19 - Issue 2 > Vulvar Lichen Sclerosus: A Comparison of the Short-term Top...
Journal of Lower Genital Tract Disease:
doi: 10.1097/LGT.0000000000000065
Original Articles: Vulva and Vagina

Vulvar Lichen Sclerosus: A Comparison of the Short-term Topical Application of Clobetasol Dipropionate 0.05% Versus Mometasone Furoate 0.1%

Murina, Filippo MD; Rehman, Subhia MD; Di Francesco, Stefania MD; Mantegazza, Valeria MD; Felice, Raffaele MD; Bianco, Vanda MD

Collapse Box


Objective: To compare the efficacy of the short-term application of clobetasol propionate 0.05% (CLB) and mometasone furoate 0.05% (MMF) in the treatment of vulvar lichen sclerosus (VLS).

Study Design: This study was a retrospective review of 96 women who were diagnosed with lichen sclerosus with a follow-up of at least 1 year. Of these 96 women, 47 were treated with the topical application of CLB and 49 were treated with the topical application of MMF. All patients received treatment for 8 weeks. The drug was administered once daily for 4 weeks and then twice weekly for another 4 weeks in combination with a moisturizing cream that was continued as maintenance therapy. Subsequently, a topical steroid was applied on an as-needed basis if symptoms recurred. Follow-up visits were scheduled at 3, 6, and 12 months. The primary endpoint was the clinical response of the patients.

Results: A mean of 77.3% of the patients were defined as responders at the 12-month observation, without any significant difference between the 2 treatment groups (CLB mean 73% vs MMF mean 81.6%, p = .2). A pronounced improvement in itching was observed after 3 months of treatment in the MMF group (p = .04), whereas the other symptoms were not significantly different between the 2 groups.

Conclusions: This study indicates that CLB 0.05% and MMF 0.1% in a short protocol regimen are effective, safe, and reliable treatments for VLS, with no significant difference between the 2 steroids in their efficacy. However, a moisturizing cream should be an integral part of the treatment.

Copyright © 2015 by the American Society for Colposcopy and Cervical Pathology


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.